<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5654">
  <stage>Registered</stage>
  <submitdate>10/07/2013</submitdate>
  <approvaldate>10/07/2013</approvaldate>
  <nctid>NCT01912937</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetic Study of Drug-coated Angioplasty Balloons in the Superficial Femoral or Popliteal Arteries:</studytitle>
    <scientifictitle>ProspectIve, SingLe-Arm, MuLti-Center, Pharmacokinetic Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon</scientifictitle>
    <utrn />
    <trialacronym>PK</trialacronym>
    <secondaryid>TP-1363</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Angioplasty treatment with the CVI Drug-coated Balloon (DCB)

Experimental: DCB Arm - Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)


Treatment: devices: Angioplasty treatment with the CVI Drug-coated Balloon (DCB)
Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Paclitaxel Levels - Measurement of paclitaxel concentration in the circulating blood immediately after last balloon deployment, 1, 4, 24 hours, 7, 14, 30, 60 days and 6 months (if applicable) post-procedure.</outcome>
      <timepoint>up to 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Freedom from Events as a Safety Measure (Composite) - Freedom from device and procedure-related death through 30 days post-procedure; and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.</outcome>
      <timepoint>up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Measurements of Pharmacokinetics variables: Cmax, Tmax, AUC</outcome>
      <timepoint>(0-t) and half-life</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or non-pregnant female greater than or equal to 18 years of age.

          -  Subjects with symptomatic leg ischemia, requiring treatment of the Superficial Femoral
             Artery (SFA) or popliteal artery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating females.

          -  Known intolerance to study medications, paclitaxel or contrast agents that in the
             opinion of the investigator cannot be adequately pre-treated.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Spectranetics Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To describe the pharmacokinetics of paclitaxel in the blood delivered from a paclitaxel
      coated percutaneous angioplasty balloon catheter as a result of treatment of de novo or
      restenotic lesion(s), occluded/stenotic or re-occluded/restenotic lesion(s).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01912937</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Holden, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>